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Edited by Hans EklundAbstract APOBEC3G is a single-strand DNA cytosine deam-
inase capable of blocking retrovirus and retrotransposon replica-
tion. APOBEC3G has two conserved zinc-coordinating motifs
but only one is required for catalysis. Here, deletion analyses
revealed that the minimal catalytic domain consists of residues
198-384. Size exclusion assays indicated that this protein is
monomeric. Many (31/69) alanine substitution derivatives of
APOBEC3G198-384 retained signiﬁcant to full levels of activ-
ity. These data corroborated an APOBEC2-based structural
model for the catalytic domain of APOBEC3G indicating that
most non-essential residues are solvent accessible and most
essential residues cluster within the protein core.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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editing; Hypermutation1. Introduction
Human APOBEC family members are important mediators
of adaptive and innate immune responses (reviewed by [1,2]).
These proteins are deﬁned by a highly conserved zinc-coordi-
nating motif, HXE-X23–28-CX2–4C, in which the histidine
and the two cysteines position zinc and the glutamate positions
water to promote the nucleophilic deamination of cytosines
within single-stranded, polynucleotide substrates (usually
DNA). One family member, APOBEC3G (A3G), was identi-
ﬁed as a cellular protein capable of blocking the replication
of virion infectivity factor (Vif)-defective HIV-1 [3]. Indepen-
dent work showed that A3G was capable of DNA cytosine
deamination [4]. Subsequent studies linked these two activities
by demonstrating that A3G could inhibit the replication ofAbbreviation: APOBEC3G, apolipoprotein BmRNA editing catalytic
subunit-like protein 3G
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doi:10.1016/j.febslet.2007.08.076HIV-1 and other retroviruses by deaminating viral cDNA
cytosines to uracils during reverse transcription [5–7]. Uracils
template the incorporation of adenines during the synthesis
of the complementary viral DNA strand, and subsequent rep-
lication (or DNA repair) ultimately produces strand-speciﬁc C/
G to T/A transition mutations (hypermutations).
The deaminase activity of A3G has been studied genetically
and biochemically [5,8–10]. It has been mapped to the con-
served C-terminal zinc-coordinating domain [9–12]. The local
dinucleotide deamination preference of A3G (5 0-CC) is readily
observed in AIDS patient-derived HIV-1 DNA sequences as
viral genomic strand 5 0-GG to 5 0-AG hypermutations (cDNA
strand 5 0-CC to 5 0-CT transition mutations; e.g. [13]). Here, an
extensive mutational analysis of A3G was performed to
delineate the minimal region required for catalysis, to deﬁne
non-essential (and essential) amino acids and to corroborate
structure-based predictions.2. Materials and methods
2.1. Plasmid constructs
The A3G cDNA used here matches NM_021822. A3G and mutant
derivatives were expressed as GST fusion proteins using pGEX6P1 or
pGEX6P2 (GE Healthsciences). An EcoRI–SalI DNA fragment from
pTrc99A-A3G encoding full-length A3G [9] was sub-cloned directly
into pGEX6P1. A3G deletion mutants were constructed by amplifying
the relevant A3G coding regions, digesting the resulting PCR products
with SmaI and SalI and ligating them into the SmaI and XhoI sites of
pGEX6P2. Alanine mutants were constructed using the QuikChange
protocol (Stratagene). All constructs were veriﬁed by DNA sequenc-
ing. An oligonucleotide table is available online.
2.2. Escherichia coli mutation assays
The E. coli-based, rifampicin-resistance (RifR) mutation assay has
been used extensively to monitor the intrinsic DNA cytosine deami-
nase activity of several A3 proteins including A3G (e.g. [4,9]). Aliquots
of saturated overnight cultures (LB plus 200 lg/mL ampicillin) were
spread onto LB plates containing 100 lg/mL rifampicin to select for
RifR mutants and diluted aliquots were spread onto LB plates contain-
ing 200 lg/mL ampicillin to determine the number of viable cells.
Mutation frequencies were calculated by dividing the number of RifR
mutants by the number of viable cells in each culture. For the deletion
experiments, the mutation frequencies of eight individual cultures were
plotted and the median indicated. For the alanine mutant experiments,
the RifR mutation frequency for each construct was determined by
assaying the median RifR mutation frequency for 8–12 independent
cultures, calculating the fold-diﬀerence relative to the median value
of the vector control cultures and averaging at least two (and up to
12) independent experiments.blished by Elsevier B.V. All rights reserved.
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4762 K.-M. Chen et al. / FEBS Letters 581 (2007) 4761–47662.3. GST-A3G expression, puriﬁcation and size exclusion procedures
GST-A3G protein levels were monitored by expressing them in
E. coli BL21 DE3 RIL (Stratagene), sonicating the cells in lysis buﬀer
(100 mM NaCl, 50 mM Na2HPO4/NaH2PO4 [pH7.0], protease inhibi-
tor [Roche]), separating the soluble (supernatant) and insoluble (pellet)
fractions by centrifugation (12110 · g, 20 min, 4 C) and fractionating
aliquots of the resulting proteins by SDS–PAGE. Proteins were de-
tected by coomassie blue and quantiﬁed by Image J software (http://
rsb.info.nih.gov/ij/). Immunoblots were done with antibodies from
GE Healthcare (anti-GST) and from J. Lingappa (anti-A3G; [11])
For size exclusion experiments, GST-A3G198-384 was bound to gluta-
thione sepharose, washed several times with lysis buﬀer, eluted with
PreScission protease (GE Healthcare) in 1 mM DTT, 50 mM Na2-
HPO4/NaH2PO4 [pH 7.0] buﬀer, quantiﬁed and immediately 1 mg
(approx. 1 mL) was passed through a Superdex 75 size exclusion col-
umn (GE Healthcare) and detected in fractions by UV (absorbance
280). GST and lysozyme were purchased from Sigma.
2.4. Structural modeling
A3G198–384 and APOBEC2 primary amino acid sequences were
aligned with the homology modeling module of the InsightII program
(Accelrys) (Online Fig. S1). Secondary structural elements of A3G198–
384 were predicted using the HNN program [14,15]. A model was gen-
erated by ﬁtting these elements (allowing for gaps) to those in the ac-
tual structure of APOBEC2 (PDB 2YNT; [16]). No gross diﬀerences in
secondary structure were observed. The homology modeling module of
the InsightII program (Accelrys) was used to construct and reﬁne the
model by minimizing energetically unfavorable amino acid side chain
interactions.28 30 32 34 36 38 40 42 44 46 48 50
Fraction Number
A2
Fig. 1. APOBEC3G deletion mutants delineate a minimal active
domain. (A) An illustration showing the amino acid boundaries used
for deletion constructs. The HXE-X23–28-CX2–4C motifs are depicted
by open boxes, and the asterisk designates the catalytic domain. (B)
RifR mutation frequencies of the indicated GST-A3G constructs. Each
X represents the mutation frequency of an individual culture (n = 8 per
construct). The median mutation frequency for cells expressing the
vector control, A3G, A3G175–384 and A3G198–384 is indicated. (C)
Size exclusion proﬁles of GST (25 kDa), A3G198–384 (22 kDa) and
lysozyme (14 kDa) indicate that A3G198–384 is monomeric.3. Results and discussion
3.1. Residues 198-384 of APOBEC3G are suﬃcient for DNA
deamination
Chimeric APOBEC3 proteins and site-directed mutants have
been used to demonstrate that the intrinsic DNA cytosine
deaminase activity of human APOBEC3G resides in the con-
served C-terminal zinc-coordinating domain [9–12]. To further
delineate the minimal domain required for catalysis, nine A3G
deletion constructs were tested for mutability in the E. coli-
based RifR mutation assay (Fig. 1). Bacteria expressing GST
showed a median of 2.5 RifR mutants per 107 viable cells.
Expression of full-length A3G fused to GST caused a 4.4-fold
increase in mutation frequency. Apart from two notable excep-
tions, all of the A3G deletion constructs were inactive. The
inactivity of constructs lacking 22 or 40 C-terminal residues
was consistent with prior work showing that A3G lacking 38
or 89 C-terminal amino acids was unable to inhibit HIVDvif
[17,18]. A more interesting result emerged from analyses of
N-terminal deletion set. A3G variants encoding residues 175-
384 or 198-384, but not 215-384, were considerably more
mutable than full-length A3G. These data demonstrated that
the entire N-terminal, zinc-binding domain is dispensable for
activity, and only A3G residues 198-384 are required.
3.2. Size exclusion experiments indicate that A3G198–384 is
monomeric
Previous studies indicated that an A3G C97A mutant was
incapable of co-immunoprecipitating wildtype A3G, but was
still capable of DNA deamination [12,19]. Consistent with these
studies, A3G198–384 proﬁled as a 22 kDa monomer in size
exclusion experiments, migrating clearly between the elution
positions of lysozyme (14 kDa) and GST (25 kDa) (Fig. 1C).
It is not likely that stable oligomeric forms of A3G198–384
exist, because fractions 1–27 did not contain protein peaks.3.3. Alanine mutations deﬁne essential and non-essential residues
of A3G198–384
To more precisely delineate the residues and domains re-
quired for DNA deamination, the A3G198–384 variant was
used to construct a series of 69 alanine mutants (Fig. 2). Muta-
genesis was concentrated to hydrophobic residues and cyste-
ines. This strategy was motivated partly by the likelihood
that some of the hydrophobic amino acids would likely be
important structurally (perhaps forming part of the enzyme
core) whereas, more intriguingly, others would be positioned
on the surface of the protein (perhaps deﬁning interaction
sites). We also envisaged that mutating select hydrophobic res-
idues might help overcome the solubility issues of A3G and
other family members [8,10,19]. All 69 mutants were analyzed
using the E. coli-based RifR mutation assay, because in vitro
experiments were hindered by the fact that A3G198–384 fre-
quently precipitated during biochemical puriﬁcation and
invariably during long-term storage.
Twelve independent RifR experiments, each with at least 10
constructs (and 8–12 independent cultures per mutant), were
required to analyze 69 alanine mutant derivatives of
A3G198–384 (Fig. 2). It was not feasible to simultaneously
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Fig. 2. Mutator phenotype of 69 APOBEC3G alanine substitution mutants. Histograms showing the relative RifR mutation frequencies of cells
expressing the vector control (), A3G198–384 (+) or derivatives with alanine substitutions at the underlined amino acid positions. Each histogram
bar reports data from two to ﬁve independent experiments, except the bars for vector and A3G198–384, which reﬂect data from 12 (±S.E.M.). The
dotted line represents the 3-fold signiﬁcance threshold that was used to distinguish active and inactive mutant constructs. A3G amino acids 198–200
and 381–384 were not shown. A predicted secondary structure of A3G198–384, based on a pair wise alignment with APOBEC2, is included to
facilitate comparisons with Fig. 4.
K.-M. Chen et al. / FEBS Letters 581 (2007) 4761–4766 4763examine all 69 mutants, and minimizing inter-experiment var-
iability was therefore important. This was done by normalizing
the median RifR mutation frequencies of cells expressing the
control vector (i.e., the spontaneous mutation frequency was
set to 1 and used as a baseline). The actual vector control val-
ues ranged from 0.8 to 3.9 RifR mutants per 107 viable cells
(n = 12 experiments). This approach readily enabled the muta-
genic eﬀects of A3G198–384 and derivatives to be compared
between multiple experiments. For instance, the ﬁrst two col-
umns of each row of Fig. 2 report the relative mutation
frequency of the vector control and A3G198–384, which in-
creased the RifR mutation frequency14.9-fold (S.E.M.: 1.5-
fold; n = 12 experiments; the actual values ranged from 15.1
to 54.5 RifR mutants per 107 viable cells). Although the raw
experimental values ﬂuctuated modestly between experiments
(attributable to factors such as incubation temperatures, fresh-
ness of the rifampicin-containing plates, colony sizes upon
counting, time in stationary phase, etc.), the small S.E.M.s
indicated that the relative inter-experiment values were
remarkably constant and therefore readily comparable.
We were ﬁrst struck by the surprising number of alanine
mutants that elicited levels of DNA deaminase activity that
were at least 3-fold greater than those of the vector control
(Fig. 2). In total, 31/69 mutants met this threshold. Several
of the other mutants also triggered mutation frequencies signif-
icantly above those of the vector control cells and above those
of cells expressing a catalytically dead A3G variant, E259A
[11,20].The second notable feature of this dataset was an obvious
clustering of non-essential and essential residues, deﬁned by
alanine substitution mutants that retained or lost signiﬁcant
activity, respectively. Approximately two-thirds of the non-
essential amino acids were found in the A3G region spanning
198-275, with 224-253 particularly striking. Conversely, the
majority of the essential residues were found in the C-terminal
interval, 276-384, suggesting that the C-terminal end of A3G is
required for the integrity of the enzyme.
Third, the alanine mutant data agreed with those from the
deletion studies. Toward the N-terminal end, F202, F206
and W211 were required for RifR mutagenesis, explaining
why all of the A3G variants starting at position 215 were inac-
tive. Similarly, L364, L375, I378 and L379 were clearly
required, oﬀering a reasonable explanation for why all three
C-terminal deletion constructs were inactive.
3.4. A3G198–384 and derivative mutator activities are not
simply explained by expression levels
To help exclude the possibility that a lack of deaminase
activity might simply be due to reduced solubility or expres-
sion, the relative abundance of each protein was analyzed by
SDS–PAGE. Rather than examine whole cell extracts, the sol-
uble (supernatant) and insoluble (pellet) fractions were consid-
ered separately (the sum of course reﬂecting whole cell levels).
A representative coomassie-stained gel is shown for the ﬁrst
ﬁve GST-A3G198-384 derivatives, F202A, F204A, F206A,
W211A and V212A (Fig. 3A). The supernatant/pellet ratio
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Fig. 3. GST-A3G198-384 expression data. (A) A representative gel
showing the soluble (supernatant) and insoluble (pellet) amounts of
GST, GST-A3G198-384 (WT) and 5 mutant derivatives. The S/P ratio
of the boxed bands is shown below each lane. The E. coli protein(s)
that migrates indistinguishably from GST-A3G198-384 was present in
every sample and it provided a constant (but lower) background signal.
(B) Anti-GST (left panel) and anti-A3G (right panel) immunoblots
conﬁrm the identities of the bands boxed in A. (C) Mutants with
higher, near equivalent or lower S/P values than those of wild type
GST-A3G198–384 are listed. Total protein amounts (S + P) were
similar for every construct ([A] and data not shown).
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indicating that the low activity levels for F202A, F206A and
V212A were not simply due to solubility or expression deﬁcien-
cies. Anti-GST and anti-A3G immunoblots conﬁrmed the
identity of the coomassie-stained bands (Fig. 3B). The over-
whelming majority of the remaining mutants were as soluble
and some were even more soluble than GST-A3G198-348
(Fig. 3C). However, six mutants were less soluble. Four of
these mutants, L260A, C261A, C281A and C308A, caused sig-
niﬁcant mutation frequency increases indicating that these mu-
tants are catalytically active and that the corresponding
mutation frequencies may be underestimates. Correction fac-
tors were not calculated because these mutants did not impact
major conclusions. However, two of the six less soluble
mutants, W269A and C288A (one of the conserved zinc-coor-
dinating positions), showed no activity. We were therefore un-
able to determine whether this was due to gross insolubility, to
a loss of enzyme activity or to both of these reasons. Neverthe-
less, the expression data indicated that vast majority of
mutants are well expressed and modestly soluble and, there-
fore, that the corresponding E. coli-based activity data are
informative.3.5. The DNA deaminase results corroborate a predicted 3D
structure for A3G198–384
To begin to address whether there was a correlation between
activity level and structural position, we used the APOBEC2
crystal structure to model A3G198–384 (Fig. 4). Side-chains
of all of the mutated residues were added to the model and col-
ored green or red, representing non-essential or essential resi-
dues, respectively. This scheme revealed two striking
correlations. First, the amino acid side chains of most of the
essential residues positioned toward the core of the protein,
facing inward and away from solvent-accessible areas. Second,
most of the amino acid side chains of the residues that were not
required for DNA deamination appeared in external, solvent
accessible spaces. A particularly interesting (and apparently
dispensable) cluster was located within the predicted b1-
loop-b2-loop region (M227, W232, V233, L234, L235, F241,
L242, C243, F252 and L253). It is tempting to speculate that
this region constitutes a protein interaction surface, possibly
involved in an association with the N-terminal half of A3G.
Such a possibility is supported by the APOBEC2 crystal struc-
ture, which shows that the analogous b2 strand forms exten-
sive anti-parallel contacts with the b2 strand of another
APOBEC2 molecule resulting in a dimer. Analogous contacts
may zip-together the N- and the C-terminal halves of A3G.
The structural model also aﬀorded reasonable explanations
for the essential nature of the N- and C-terminal ends of
A3G198–384 (Fig. 4). N-terminal residues preceding the b1
strand may help stabilize the b-sheet core of A3G198–384 such
that removing (or mutating) these N-terminal residues would
likely cause a5 to dissociate from the core and thereby render
the resulting protein non-functional. Similarly, the C-terminal
domain a5 helix appears positioned to help stabilize the zinc-
coordinating active site, which consists of b1, b3, b4, a1 and
a2.
The structural model for A3G198–384 is likely to be reason-
ably accurate because 31/35 of the hydrophobic residues re-
quired for DNA deaminase activity are similar (11/31) or
identical (20/31) to homologous amino acids in APOBEC2.
Many of the 31 residues are located within or near predicted
secondary structural elements, which are probably required
for hydrophobic interactions that maintain the overall struc-
tural integrity of the enzyme. These residues include L220
and Y222 in b1, F262, I266 and W269 in a1, Y277, V279
and F282 in b3, M295 in a2, V305, L307, I309, I314 and
Y315 in b4, L325 and L328 in a3, I335 and M338 in b5,
F343, W347, F350 and V351 in a4 and L364, L375, I378
and L379 in a5. The strong correlation between conservation
and activity is further bolstered by the periodicity of the corre-
lation – apparent at every other residue in b-strands and every
three or four residues in a-helices. The amino acid side chains
of these important residues are facing toward the inside of the
protein structure (Fig. 4). Moreover, these correlations are
even more striking when one considers that fact that these
two proteins have less than 40% identity overall. Therefore,
the E. coli-based mutation data strongly indicate that both
the secondary structural elements and the overall three-
dimensional folds of A3G198–384 are similar to those of
APOBEC2.
A major unanswered question is how does A3G bind DNA?
One clue may be provided by the location of the conserved
HXE-X23–28-CX2–4C active site, which appeared uniquely
positioned on the outside of the predicted structure, with the
Fig. 4. Four views of a model A3G198–384 structure based on human APOBEC2 [16]. The predicted a helices and b sheets correspond with those
shown in Fig. 2. Relevant amino acid side chains are depicted in green or red to reﬂect the activity or inactivity, respectively, of an alanine
substitution at that position. The purple amino acid side chains in the top left panel represent the zinc (purple ball)-coordinating histidine (H257 in
a1) and cysteine residues (C288 and C291 in a2).
K.-M. Chen et al. / FEBS Letters 581 (2007) 4761–4766 4765zinc-coordinating histidine and the two cysteines appearing to-
ward the ends of a1 and a2 helices, respectively (Fig. 4). This
positioning together with the monomeric nature of A3G198–
384 suggested that single-strand DNA may be contacted by
these two helices. The structural model and functional data
presented here, together with a full-length A3G model pub-
lished recently [21], will provide a solid foundation for future
structure–function studies of A3G and other APOBEC family
members.
Acknowledgements: This work was supported by NIH Grants
AI064046 (RSH) and AI073167 (HM) and by the University of Min-
nesota’s Leukemia Research Fund (RSH) and Grant-in-Aid Program
(HM). R.S.H. is a Searle Scholar and a University of Minnesota
McKnight Land Grant Assistant Professor. We thank A. Briggs, P.
Gross and Y. Sham for technical assistance, Harris and Matsuo labo-
ratory members for helpful discussions and the University of Minne-
sota AGAC and SCI for DNA sequencing and computational
resources, respectively.Appendix A. Supplementary data
Supplementary data associated with this article can be
found, in the online version, at doi:10.1016/j.febslet.2007.
08.076.References
[1] Cullen, B.R. (2006) Role and mechanism of action of the
APOBEC3 family of antiretroviral resistance factors. J. Virol.
80, 1067–1076.
[2] Longerich, S., Basu, U., Alt, F. and Storb, U. (2006) AID in
somatic hypermutation and class switch recombination. Curr.
Opin. Immunol. 18, 164–174.
[3] Sheehy, A.M., Gaddis, N.C., Choi, J.D. and Malim, M.H. (2002)
Isolation of a human gene that inhibits HIV-1 infection and is
suppressed by the viral Vif protein. Nature 418, 646–650.
[4] Harris, R.S., Petersen-Mahrt, S.K. and Neuberger, M.S. (2002)
RNA editing enzyme APOBEC1 and some of its homologs can
act as DNA mutators. Mol. Cell 10, 1247–1253.
[5] Harris, R.S., Bishop, K.N., Sheehy, A.M., Craig, H.M., Petersen-
Mahrt, S.K., Watt, I.N., Neuberger, M.S. and Malim, M.H.
(2003) DNA deamination mediates innate immunity to retroviral
infection. Cell 113, 803–809.
[6] Mangeat, B., Turelli, P., Caron, G., Friedli, M., Perrin, L. and
Trono, D. (2003) Broad antiretroviral defence by human APO-
BEC3G through lethal editing of nascent reverse transcripts.
Nature 424, 99–103.
[7] Zhang, H., Yang, B., Pomerantz, R.J., Zhang, C., Arunachalam,
S.C. and Gao, L. (2003) The cytidine deaminase CEM15 induces
hypermutation in newly synthesized HIV-1 DNA. Nature 424,
94–98.
[8] Chelico, L., Pham, P., Calabrese, P. and Goodman, M.F. (2006)
APOBEC3G DNA deaminase acts processively 3 0 ﬁ 5 0 on single-
stranded DNA. Nat. Struct. Mol. Biol. 13, 392–399.
[9] Hache´, G., Liddament, M.T. and Harris, R.S. (2005) The
retroviral hypermutation speciﬁcity of APOBEC3F and
4766 K.-M. Chen et al. / FEBS Letters 581 (2007) 4761–4766APOBEC3G is governed by the C-terminal DNA cytosine
deaminase domain. J. Biol. Chem. 280, 10920–10924.
[10] Iwatani, Y., Takeuchi, H., Strebel, K. and Levin, J.G. (2006)
Biochemical activities of highly puriﬁed, catalytically active
human APOBEC3G: correlation with antiviral eﬀect. J. Virol.
80, 5992–6002.
[11] Newman, E.N., Holmes, R.K., Craig, H.M., Klein, K.C.,
Lingappa, J.R., Malim, M.H. and Sheehy, A.M. (2005) Antiviral
function of APOBEC3G can be dissociated from cytidine
deaminase activity. Curr. Biol. 15, 166–170.
[12] Navarro, F., Bollman, B., Chen, H., Konig, R., Yu, Q., Chiles, K.
and Landau, N.R. (2005) Complementary function of the two
catalytic domains of APOBEC3G. Virology 333, 374–386.
[13] Janini, M., Rogers, M., Birx, D.R. and McCutchan, F.E. (2001)
Human immunodeﬁciency virus type 1 DNA sequences geneti-
cally damaged by hypermutation are often abundant in patient
peripheral blood mononuclear cells and may be generated during
near-simultaneous infection and activation of CD4(+) T cells. J.
Virol. 75, 7973–7986.
[14] Combet, C., Blanchet, C., Geourjon, C. and Deleage, G. (2000)
NPS@: network protein sequence analysis. Trends Biochem. Sci.
25, 147–150.
[15] Guermeur, Y., Geourjon, C., Gallinari, P. and Deleage, G. (1999)
Improved performance in protein secondary structure predictionby inhomogeneous score combination. Bioinformatics 15, 413–
421.
[16] Prochnow, C., Bransteitter, R., Klein, M.G., Goodman, M.F. and
Chen, X.S. (2007) The APOBEC-2 crystal structure and func-
tional implications for the deaminase AID. Nature 445, 447–451.
[17] Li, J., Potash, M.J. and Volsky, D.J. (2004) Functional domains
of APOBEC3G required for antiviral activity. J. Cell Biochem.
92, 560–572.
[18] Shindo, K., Takaori-Kondo, A., Kobayashi, M., Abudu, A.,
Fukunaga, K. and Uchiyama, T. (2003) The enzymatic activity of
CEM15/Apobec-3G is essential for the regulation of the infectiv-
ity of HIV-1 virion but not a sole determinant of its antiviral
activity. J. Biol. Chem. 278, 44412–44416.
[19] Opi, S. et al. (2006) Monomeric APOBEC3G is catalytically
active and has antiviral activity. J. Virol. 80, 4673–4682.
[20] Jonsson, S.R., Hache, G., Stenglein, M.D., Fahrenkrug, S.C.,
Andresdottir, V. and Harris, R.S. (2006) Evolutionarily conserved
and non-conserved retrovirus restriction activities of artiodactyl
APOBEC3F proteins. Nucleic Acids Res. 34, 5683–5694.
[21] Zhang, K.L., Mangeat, B., Ortiz, M., Zoete, V., Trono, D.,
Telenti, A. and Michielin, O. (2007) Model structure of human
APOBEC3G. PLoS ONE 2, e378.
